🚨Big news for the RET positive patients👉Selpercatinib demonstrates superior PFS vs PD-1 Inhibitor+ Chemotherapy for Newly-Diagnosed RET+ Non-Small Cell Lung Cancer.
Knew this baby would graduate with honors right from the 1st ever patient enrolled on the trial. #NSCLC#LCSM #PrecisionMedicine 🎯🧬
👉Still recalling the call to the company after the first-ever patient in the study during the initial week. "This drug is highly potent. We must act swiftly to reach the dose & secure rapid FDA approval. Our patients needed it yesterday" @OncoAlert@OncBrothers
Congrats to all @RETpositive patients, global investigators, trial staff & colleagues @LoxoLillyOnc
👉Links to practice changing papers in @NEJM x2 and @TheLancetOncol & Press release
👉https://t.co/M483whloyf
👉
https://t.co/gfpwvAx6YI
👉
https://t.co/ZhJdUqAbtP
👉
https://t.co/JbXI4Rwd41